NO20030155D0 - Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav - Google Patents

Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav

Info

Publication number
NO20030155D0
NO20030155D0 NO20030155A NO20030155A NO20030155D0 NO 20030155 D0 NO20030155 D0 NO 20030155D0 NO 20030155 A NO20030155 A NO 20030155A NO 20030155 A NO20030155 A NO 20030155A NO 20030155 D0 NO20030155 D0 NO 20030155D0
Authority
NO
Norway
Prior art keywords
methods
pharmaceutical compositions
aryl substituted
amines
nicotinic compounds
Prior art date
Application number
NO20030155A
Other languages
English (en)
Other versions
NO20030155L (no
Inventor
Gary Maurice Dull
Jean-Pierre Leconte
Humayun Kabir
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20030155D0 publication Critical patent/NO20030155D0/no
Publication of NO20030155L publication Critical patent/NO20030155L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20030155A 2000-07-14 2003-01-13 Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav NO20030155L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/616,743 US6432954B1 (en) 2000-07-14 2000-07-14 Pharmaceutical compositions and methods for use
PCT/US2001/021872 WO2002005798A2 (en) 2000-07-14 2001-07-11 Pharmaceutical compositions for treating neurological disorders

Publications (2)

Publication Number Publication Date
NO20030155D0 true NO20030155D0 (no) 2003-01-13
NO20030155L NO20030155L (no) 2003-03-13

Family

ID=24470778

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030155A NO20030155L (no) 2000-07-14 2003-01-13 Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav

Country Status (16)

Country Link
US (1) US6432954B1 (no)
EP (1) EP1311265B1 (no)
JP (1) JP2004509851A (no)
CN (2) CN1680326A (no)
AT (1) ATE285773T1 (no)
AU (2) AU2002222909B2 (no)
BR (1) BR0112130A (no)
CA (1) CA2415901A1 (no)
DE (1) DE60108130T2 (no)
HU (1) HUP0301553A3 (no)
IL (3) IL153577A0 (no)
NO (1) NO20030155L (no)
NZ (1) NZ523606A (no)
PL (1) PL360532A1 (no)
WO (1) WO2002005798A2 (no)
ZA (1) ZA200300135B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
KR20070004106A (ko) * 2004-04-21 2007-01-05 바스프 악티엔게젤샤프트 살진균성 혼합물
US7459469B2 (en) * 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
CN101528698A (zh) * 2006-05-09 2009-09-09 阿斯利康公司 (2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式
AR062860A1 (es) * 2006-09-15 2008-12-10 Astrazeneca Ab Combinaciones terapeuticas 482
US20100028447A1 (en) * 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
JP2010535237A (ja) * 2007-07-31 2010-11-18 ターガセプト・インコーポレイテッド （２ｓ）−（４ｅ）−ｎ−メチル−５−（３−（５−イソプロポキシピリジン）イル）−４−ペンテン−２−アミンの経皮投与
WO2011146009A1 (en) 2010-05-20 2011-11-24 Targacept Inc. New process for the preparation of aryl substituted olefinic amines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1409551A (en) 1972-04-14 1975-10-08 Allen & Hanburys Ltd Cyclopent a indene derivatives
US4528290A (en) 1984-01-30 1985-07-09 Eli Lilly And Company Stimulating dopamine D-1 receptors
GB8606254D0 (en) 1986-03-13 1986-04-16 Wyeth John & Brother Ltd Substituted pyrimidoindoles
FR2664600B1 (fr) 1990-07-16 1994-09-02 Rhone Poulenc Sante Nouveau sel derive de la dialcoylaminoalcoyl-sulfonyl-26 pristinamycine iib.
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
IL115305A0 (en) * 1994-09-14 1995-12-31 Lundbeck & Co As H Carbamolyloxy amine compounds
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
JP3603177B2 (ja) * 1998-03-26 2004-12-22 参天製薬株式会社 新規ウレア誘導体
ES2150353B1 (es) * 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
ES2228054T3 (es) * 1998-06-16 2005-04-01 Targacept, Inc. Aminas olefinicas sustituidas con arilo y su uso como agonistas de receptores colinergicos.
DE10032456A1 (de) * 2000-07-04 2002-01-31 Lohmann Therapie Syst Lts Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen
US6743812B1 (en) * 2000-07-14 2004-06-01 Targacept, Inc. Pharmaceutical compositions and methods for use

Also Published As

Publication number Publication date
EP1311265B1 (en) 2004-12-29
HUP0301553A3 (en) 2005-05-30
NO20030155L (no) 2003-03-13
DE60108130T2 (de) 2006-02-23
DE60108130D1 (de) 2005-02-03
AU2290902A (en) 2002-01-30
CA2415901A1 (en) 2002-01-24
CN1468100A (zh) 2004-01-14
WO2002005798A3 (en) 2003-03-13
EP1311265A2 (en) 2003-05-21
ZA200300135B (en) 2004-04-06
JP2004509851A (ja) 2004-04-02
ATE285773T1 (de) 2005-01-15
AU2002222909B2 (en) 2005-12-15
BR0112130A (pt) 2003-09-02
US6432954B1 (en) 2002-08-13
IL153577A (en) 2009-07-20
WO2002005798A2 (en) 2002-01-24
NZ523606A (en) 2004-12-24
HUP0301553A2 (hu) 2003-08-28
CN1680326A (zh) 2005-10-12
IL192287A0 (en) 2008-12-29
PL360532A1 (en) 2004-09-06
IL153577A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
IL192287A0 (en) Pharmaceutical compositions and methods for use
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
DE60025604D1 (de) Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DK0900200T3 (da) Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet
IS2293B (is) Arýl sambrædd asapólýsýklísk efnasambönd
EA200401365A1 (ru) Способы лечения илеуса
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
NO20030724D0 (no) Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
DE69837322D1 (de) Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
BR0112131A (pt) Composições farmacêuticas e métodos para uso
NO20071466L (no) 3-substituerte-5- og 6-aminoalkyl indol-2-karboksylsyreamider og relaterte analoger som inhibitorer av kaseinkinase IE
DK1218401T3 (da) 4-Benzylaminoquinolin-konjugat med galdesyre og deres heteroanaloger, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
ATE293602T1 (de) 2-aminopyridine als inhibitoren von cyclooxygenase-2
DE602004021114D1 (de) Verwendung von cyclischen bioisosteren von purin-system-derivaten zur behandlung von erkrankungen durch störungen der nitrergen und dopaminergen systeme
ATE372117T1 (de) Verwendung von 1,3-diazadibenzo(e,h) azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application